Innate lymphoid cells type 2 in LTP‐allergic patients and their modulation during sublingual immunotherapy.

(A) ILC2 percentages in LTP-allergic patients (LTP-AP, N = 10) and tolerant controls (TC, N = 10); (B) Correlation of the IL-4+ and IL-13+ILC2 percentages vs clinical parameters. Lipid transfer protein allergy induces complex clinical manifestations, often severe or life-threatening in food allergy (FA).1 It is characterised by an immunologic tolerance breakdown to ingested food associated with the immunological response type 2. We report for the first time ILC2 implication in LTP allergy and SLIT-Prup3 ability to modulate effector Th2 cells and ILC2 in LTP-allergic patients (LTP-AP). [Extracted from the article]